Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Volitionrx Ltd filings on SEC EDGAR ↗
VolitionRx reported total revenues of $3.0 million for the nine months ended September 30, 2026, a significant increase from $1.3 million in the prior year, primarily driven by product sales. Despite higher revenues, the company recorded a net loss of $17.8 million for the period, impacted by $15.9 million in operating expenses and $5.0 million in other expenses including debt extinguishment costs.
VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.
Term
Q3 2026
“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”
Cameron Reynolds, President and Group Chief Executive Officer
VolitionRx CEO Cameron Reynolds agreed to a further temporary reduction in his annual base salary from $355,456 to $236,970.50 as part of the company's cost-reduction measures. This follows a previous 25% reduction effective February 2026, bringing his total salary down from a contractual base of $473,941. The reduction will remain in effect until the Compensation Committee determines the company's financial stability is secured, potentially following a significant licensing or commercial agreement.
Volitionrx $500K Debt Financing with Lind Global Asset Management XII LLC
VolitionRx entered into a waiver and consent agreement with Lind Global Asset Management to make a $500,000 partial cash prepayment on a senior secured convertible promissory note, reducing the outstanding balance to approximately $0.7 million. The agreement also defers monthly repayments for November and December 2026 and pauses Lind's conversion rights until January 1, 2027, unless the stock price reaches $0.275.
Volitionrx $525K Debt Financing with Lind Global Asset Management XII LLC
VolitionRx Limited issued an aggregate of 2,157,340 shares of common stock to Lind Global Asset Management XII LLC to satisfy $525,000 in conversion obligations under a senior secured convertible promissory note. The shares were issued in two tranches on September 18 and September 23, 2026, as part of the settlement of an existing debt instrument originally issued in May 2025.